Evolution and clinical implications of the myofibroblast concept
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Time for primary review 21 days. The phenomena of wound contraction and scar retraction are known since old ages (for review see [1]). In the first part of our century, the work of Carrel and Lecomte du Noüy has contributed to the notion that the forces producing wound contraction are generated within the granulation tissue itself [2]. These forces were generally considered to depend on extracellular matrix rearrangements; however, Abercrombie and co-workers reported, in the fifties, that fibroblasts exert tractional forces in vitro [3]. Similarly, Hoffmann-Beerling showed that addition of ATP to permeabilized fibroblasts in culture produces a contraction of their cytoplasm [4]. In this context, and in the context of emerging work on cytoskeleton morphology and function [5], the ultrastructural observation made in our laboratory in 1971 that during granulation tissue evolution fibroblasts acquire smooth muscle (SM) cell features, such as the presence of cytoplasmic microfilament bundles [6], lead to the proposition that these cells are the source of the force producing wound contraction, and probably connective tissue retraction during fibrotic phenomena. Shortly thereafter, it was shown that strips of granulation tissue isolated and placed in a pharmacological bath would contract and relax under the influence of substances which are known to be capable of contracting and relaxing SM cells [7, 8]. It is noteworthy (particularly because this observation has never been developed) that granulation tissues from different locations respond differently to the same agonist or antagonist stimulus, suggesting that the capacity to react with contraction to a given stimulus by fibroblastic cells depends on their location [8]. The name myofibroblast was suggested for this modified and possibly contractile fibroblast [7]. During the next few years, several laboratories reported by means of ultrastructural techniques the presence of myofibroblasts in several lesions characterized by fibrosis and retraction such as fibromatoses [9], liver cirrhosis [10], pulmonary [11] and renal [12] fibrosis. The presence of myofibroblasts was also shown in normal tissues in locations where a certain degree of tension was needed to function, such as the theca externa of the ovary [13], the alveolar septum [14] and the intestinal pericriptal cells [15]. Hence, the concept was developed that in both normal and pathological situations myofibroblasts develop in response to traction stimuli and can exert a force producing tissue resistance and, particularly in pathological cases, tissue deformation (for review see [16]). Because of the emerging concept that non-muscle cells contain contractile proteins, which up to that time had been considered typical of muscle cells, and because of the description of other cytoskeletal structures, such as microtubules and intermediate filaments, a considerable effort was made by our as well as some other laboratories in the characterization of contractile and cytoskeletal elements present in myofibroblasts (for review see [17]). It was shown that myofibroblasts contain higher amounts of polymerized actin, as compared to normal fibroblasts in vivo [18]. It was also shown that normal tissues containing myofibroblasts, such as the lung alveolus, would produce contraction upon the stimulus of agents contracting SM cells [19]. A significant advance was the production of an antibody against α-SM actin [20], one of the six actin isoforms present in mammalian tissues and considered to be typical for vascular SM cells [21]. The use of this antibody showed that α-SM actin is expressed temporarily in granulation tissue of an experimental wound and disappears when the scar develops [22]. Thus, an actin isoform typical of SM cells is expressed during wound healing in granulation tissue fibroblasts; this expression coincides with the phenomenon of wound contraction. Studies by several laboratories demonstrated the presence of α-SM actin in myofibroblastic cells present in fibrotic tissues of different organs such as the liver [23, 24], the lung [25], the kidney [26], the heart [27, 28] and the breast [29–31]; moreover, α-SM actin was suggested as the most significant marker of myofibroblastic cells, at least in pathological settings [17]. The presence of myofibroblasts in myocardial granulation tissue following an infarct has been shown by means of ultrastructure [32] to persist for a long time. The finding was confirmed by immunohistochemistry [33]. It is noteworthy that in old myocardial scars, fibroblastic cells still express α-SM actin, probably because of the continuous tension present in these areas [27]. In myocardial, as well as in cutaneous granulation tissue myofibroblasts are spatially highly organized. Recently, it has been shown that the myocardial myofibroblasts express a homologue of drosophila tissue polarity gene, frizzled, when they migrate into granulation tissue; this may represent the signal for alig
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Presence of modified fibroblasts in granulation tissue and their possible role in wound contraction
Gabbiani, G., Ryan, G. B., & Majno, G. (1971) · Experientia · doi:10.1007/bf02147594 · Cited by 1,485
Self-citationGranulation tissue as a contractile organ
Gabbiani, G., Hirschel, B. J., Ryan, G. B., Statkov, P. R., & Majno, G. (1972) · The Journal of Experimental Medicine · doi:10.1084/jem.135.4.719 · Cited by 807
Self-citationShi, Z., Wakil, A. E., & Rockey, D. C. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.20.10663 · Cited by 310
Cited by
The inflammatory response in myocardial infarction
Frangogiannis, N. (2002) · Cardiovascular Research · doi:10.1016/s0008-6363(01)00434-5 · Cited by 2,011
Cardiac fibroblasts: At the heart of myocardial remodeling
Porter, K. E., & Turner, N. A. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.05.002 · Cited by 1,010
Wang, J. H.-C. (2006) · Journal of Biomechanics · doi:10.1016/j.jbiomech.2005.05.011 · Cited by 1,002
Cucoranu, I., Clempus, R., Dikalova, A., Phelan, P. J., Ariyan, S., Dikalov, S., & Sorescu, D. (2005) · Circulation Research · doi:10.1161/01.res.0000187457.24338.3d · Cited by 786
“In the current study, we sought to (1) determine whether ROS derived from NADPH oxidases are important for TGF- 1–induced myofibroblast differentiation, (2) identify the catalytic Nox subunit that is required for SM -actin expression in response to TGF- 1, and (3) discover the mechanism by which Nox-derived ROS mediat…”
BackgroundSartore, S., Chiavegato, A., Faggin, E., Franch, R., Puato, M., Ausoni, S., & Pauletto, P. (2001) · Circulation Research · doi:10.1161/hh2401.100844 · Cited by 515
Metadata
- Authors
- Gabbiani, G.
- Venue
- Cardiovascular Research
- Publisher
- Oxford University Press (OUP)
- Published
- 1998-06
- Volume
- 38
- Issue
- 3
- Pages
- 545-548
- ISSN
- 0008-6363 (ISSN-L)
- OpenAlex
- W2007310561
- Cited by
- 146
- References
- 3
- FWCI
- 10.10
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evolution and clinical implications of the myofibroblast concept. https://app.cochat.ai/papers/10.1016/s0008-6363(98)00065-0
- The paper
- Gabbiani, G. (1998). Evolution and clinical implications of the myofibroblast concept. Cardiovascular Research. https://doi.org/10.1016/s0008-6363(98)00065-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.